Brovana Patent Expiration

Brovana is a drug owned by Lupin Inc. It is protected by 13 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 09, 2021. Details of Brovana's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110706 Formoterol tartrate process and polymorph
Nov, 2021

(3 years ago)

Expired
US6472563 Formoterol tartrate process and polymorph
Nov, 2021

(3 years ago)

Expired
US7145036 Formoterol tartrate polymorph
Nov, 2021

(3 years ago)

Expired
US6720453 Formoterol tartrate polymorph
Nov, 2021

(3 years ago)

Expired
US7348362 Bronchodilating β-agonist compositions and methods
Jun, 2021

(3 years ago)

Expired
US6667344 Bronchodilating compositions and methods
Jun, 2021

(3 years ago)

Expired
US6814953 Bronchodilating compositions and methods
Jun, 2021

(3 years ago)

Expired
US7473710 Bronchodilating beta-agonist compositions and methods
Jun, 2021

(3 years ago)

Expired
US7541385 Bronchodilating β-agonist compositions and methods
Jun, 2021

(3 years ago)

Expired
US7462645 Bronchodilating beta-agonist compositions and methods
Jun, 2021

(3 years ago)

Expired
US7465756 Bronchodilating beta-agonist compositions and methods
Jun, 2021

(3 years ago)

Expired
US6040344 Formoterol process
Nov, 2016

(7 years ago)

Expired
US6589508 Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Apr, 2013

(11 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brovana's patents.

Given below is the list of recent legal activities going on the following patents of Brovana.

Activity Date Patent Number
Patent litigations
Expire Patent 11 Mar, 2024 US8110706
Maintenance Fee Reminder Mailed 25 Sep, 2023 US8110706
Payment of Maintenance Fee, 12th Year, Large Entity 25 Sep, 2020 US7541385
Payment of Maintenance Fee, 12th Year, Large Entity 29 Jun, 2020 US7473710
Payment of Maintenance Fee, 12th Year, Large Entity 09 Jun, 2020 US7465756
Payment of Maintenance Fee, 12th Year, Large Entity 02 Jun, 2020 US7462645
Payment of Maintenance Fee, 12th Year, Large Entity 18 Sep, 2019 US7348362
Payment of Maintenance Fee, 8th Year, Large Entity 07 Aug, 2019 US8110706
Payment of Maintenance Fee, 12th Year, Large Entity 05 Jun, 2018 US7145036
Change in Power of Attorney (May Include Associate POA) 13 Nov, 2015 US7465756

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Brovana is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Brovana's family patents as well as insights into ongoing legal events on those patents.

Brovana's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Brovana's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 09, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Brovana Generic API suppliers:

Arformoterol Tartrate is the generic name for the brand Brovana. 13 different companies have already filed for the generic of Brovana, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Brovana's generic

How can I launch a generic of Brovana before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Brovana's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Brovana's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Brovana -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
Eq. 0.015 mg base/ 2 mL 01 Oct, 2009 1 09 Nov, 2021 Extinguished





About Brovana

Brovana is a drug owned by Lupin Inc. It is used for maintenance treatment of bronchoconstriction in patients with COPD. Brovana uses Arformoterol Tartrate as an active ingredient. Brovana was launched by Lupin in 2006.

Approval Date:

Brovana was approved by FDA for market use on 06 October, 2006.

Active Ingredient:

Brovana uses Arformoterol Tartrate as the active ingredient. Check out other Drugs and Companies using Arformoterol Tartrate ingredient

Treatment:

Brovana is used for maintenance treatment of bronchoconstriction in patients with COPD.

Dosage:

Brovana is available in solution form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.015MG BASE/2ML SOLUTION Prescription INHALATION